Analyst Ratings For SAGE Therapeutics (NASDAQ:SAGE)
Today, SunTrust Banks raised its price target on SAGE Therapeutics (NASDAQ:SAGE) to per share.
Some recent analyst ratings include
- 2/26/2018-Morgan Stanley initiated coverage with a Overweight rating.
- 2/23/2018-Needham & Company LLC Reiterated Rating of Buy.
- 1/10/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
- 12/11/2017-Cowen Reiterated Rating of Buy.
- 12/8/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 12/7/2017-Raymond James Financial Reiterated Rating of Buy.
Recent Insider Trading Activity For SAGE Therapeutics (NASDAQ:SAGE)
SAGE Therapeutics (NASDAQ:SAGE) has insider ownership of 6.10% and institutional ownership of 87.33%.
- On 1/10/2018 Stephen Kanes, Insider, sold 44,000 with an average share price of $177.18 per share and the total transaction amounting to $7,795,920.00.
- On 12/21/2017 Jeffrey M Jonas, CEO, sold 210,247 with an average share price of $157.45 per share and the total transaction amounting to $33,103,390.15.
- On 12/14/2017 Albert Robichaud, Insider, sold 60,000 with an average share price of $159.43 per share and the total transaction amounting to $9,565,800.00.
- On 1/13/2017 Kimi Iguchi, CFO, sold 10,000 with an average share price of $53.92 per share and the total transaction amounting to $539,200.00.
- On 11/17/2016 Kimi Iguchi, CFO, sold 4,000 with an average share price of $51.77 per share and the total transaction amounting to $207,080.00.
- On 11/11/2016 Kimi Iguchi, CFO, sold 1,500 with an average share price of $50.59 per share and the total transaction amounting to $75,885.00.
- On 9/7/2016 Kimi Iguchi, CFO, sold 2,500 with an average share price of $40.93 per share and the total transaction amounting to $102,325.00.
Recent Trading Activity for SAGE Therapeutics (NASDAQ:SAGE)
Shares of SAGE Therapeutics closed the previous trading session at 163.01 down -0.25 0.15% with shares trading hands.